These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 28741053)

  • 21. Prognostic values of baseline, interim and end-of therapy
    Zhou Y; Zhao Z; Li J; Zhang B; Sang S; Wu Y; Deng S
    Cancer Manag Res; 2019; 11():6871-6885. PubMed ID: 31413633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation of the ΔSUV
    Itti E; Blanc-Durand P; Berriolo-Riedinger A; Kanoun S; Kraeber-Bodéré F; Meignan M; Gat E; Gouill SL; Casasnovas RO; Bodet-Milin C
    J Nucl Med; 2023 Nov; 64(11):1706-1711. PubMed ID: 37734837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC).
    Fallanca F; Alongi P; Incerti E; Gianolli L; Picchio M; Kayani I; Bomanji J
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1837-48. PubMed ID: 27154522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interim FDG-PET/CT in Hodgkin lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET).
    Annunziata S; Cuccaro A; Calcagni ML; Hohaus S; Giordano A; Rufini V
    Ann Nucl Med; 2016 Oct; 30(8):588-92. PubMed ID: 27246952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Semiquantitative analysis of interim
    Ribeiro T; Marques A; Ferreira G; Castro C; Tavares M; Espírito-Santo A; Moreira C; Mariz J
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021; 40(5):281-286. PubMed ID: 34425968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimisation of metabolic criteria in the prognostic assessment in patients with lymphoma. A multicentre study.
    Del Puig Cózar-Santiago M; García-Garzón JR; Moragas-Freixa M; Soler-Peter M; Bassa Massanas P; Sánchez-Delgado M; Sanchez-Jurado R; Aguilar-Barrios JE; Sanz-Llorens R; Ferrer-Rebolleda J
    Rev Esp Med Nucl Imagen Mol; 2017; 36(5):304-311. PubMed ID: 28483373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of baseline and interim [
    Yadgarov MY; Dunaykin MM; Shestopalov GI; Kailash C; Kireeva ED; Myakova NV; Likar YN
    Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):1955-1964. PubMed ID: 38351389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined prognostic role of TARC and interim
    Husi K; Pinczés LI; Fejes Z; Nagy B; Illés Á; Miltényi Z
    Hell J Nucl Med; 2022; 25(2):125-131. PubMed ID: 35913858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic Value of Pre-Autologous Stem Cell Transplantation PET/CT in Diffuse Large B-Cell Lymphoma: The Deauville Score Is Prognostically Superior to ΔSUVmax.
    Zhang XY; Song L; Wang PJ; Wang L; Li Y; Wang YY; Shi CL
    Acta Haematol; 2020; 143(2):124-130. PubMed ID: 31382264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria.
    Le Roux PY; Gastinne T; Le Gouill S; Nowak E; Bodet-Milin C; Querellou S; Mahe B; Dubruille V; Blin N; Salaun PY; Bodere-Kraeber F
    Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1064-71. PubMed ID: 21308370
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial.
    Kurch L; Hasenclever D; Kluge R; Georgi T; Tchavdarova L; Golombeck M; Sabri O; Eggert A; Brenner W; Sykora KW; Bengel FM; Rossig C; Körholz D; Schäfers M; Feuchtinger T; Bartenstein P; Ammann RA; Krause T; Urban C; Aigner R; Gattenlöhner S; Klapper W; Mauz-Körholz C
    Pediatr Blood Cancer; 2019 Mar; 66(3):e27539. PubMed ID: 30426671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SUV
    Texte E; Lequesne J; Tilly H; Jardin F; Vera P; Stamatoullas A; Becker S
    Leuk Lymphoma; 2021 May; 62(5):1088-1097. PubMed ID: 33289431
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interim FDG
    Duarte S; Roque A; Saraiva T; Afonso C; Marques BA; Lima CB; Neves D; Lai AC; Costa G; Cipriano A; Geraldes C; Ruzickova L; Carda JP; Gomes M
    Clin Lymphoma Myeloma Leuk; 2023 Feb; 23(2):e107-e116. PubMed ID: 36567213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of therapeutic evaluation criteria in FDG-PET/CT in patients with diffuse large-cell B-cell lymphoma: Prognostic impact of tumor/liver ratio.
    Toledano MN; Vera P; Tilly H; Jardin F; Becker S
    PLoS One; 2019; 14(2):e0211649. PubMed ID: 30730936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDG-PET/CT at the end of immuno-chemotherapy in follicular lymphoma: the prognostic role of the ratio between target lesion and liver SUV
    Annunziata S; Cuccaro A; Tisi MC; Hohaus S; Rufini V
    Ann Nucl Med; 2018 Jun; 32(5):372-377. PubMed ID: 29464479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FDG PET/CT response in diffuse large B-cell lymphoma: Reader variability and association with clinical outcome.
    Han EJ; O JH; Yoon H; Jung SE; Park G; Choi BO; Cho SG
    Medicine (Baltimore); 2016 Sep; 95(39):e4983. PubMed ID: 27684851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 18F-FDG PET/CT for Prognostic Stratification of Patients With Extranodal Natural Killer/T-Cell Lymphoma.
    Qin C; Yang S; Sun X; Xia X; Li C; Lan X
    Clin Nucl Med; 2019 Mar; 44(3):201-208. PubMed ID: 30624268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers.
    Biggi A; Gallamini A; Chauvie S; Hutchings M; Kostakoglu L; Gregianin M; Meignan M; Malkowski B; Hofman MS; Barrington SF
    J Nucl Med; 2013 May; 54(5):683-90. PubMed ID: 23516309
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Burggraaff CN; Eertink JJ; Lugtenburg PJ; Hoekstra OS; Arens AIJ; de Keizer B; Heymans MW; van der Holt B; Wiegers SE; Pieplenbosch S; Boellaard R; de Vet HCW; Zijlstra JM;
    J Nucl Med; 2022 Jul; 63(7):1001-1007. PubMed ID: 34675112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. qPET - a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma.
    Hasenclever D; Kurch L; Mauz-Körholz C; Elsner A; Georgi T; Wallace H; Landman-Parker J; Moryl-Bujakowska A; Cepelová M; Karlén J; Álvarez Fernández-Teijeiro A; Attarbaschi A; Fosså A; Pears J; Hraskova A; Bergsträsser E; Beishuizen A; Uyttebroeck A; Schomerus E; Sabri O; Körholz D; Kluge R
    Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1301-8. PubMed ID: 24604592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.